MUC5B and COVID-19: Interestingly, dexamethasone, which is commonly given to treat SARS‐CoV‐2 pneumonia,28 diminished MUC5B‐induced mucus accumulation in an in vitro model, but since most patients already receive dexamethasone to treat COVID‐19, it is unclear whether administering additional upfront broad anti‐inflammatory therapies would necessarily further lower the risk for post‐COVID‐19 fibrosis.